Creative Medical Technology
2007 W Peoria Avenue
Phoenix
Arizona
85029
United States
Tel: 602-680-7439
About Creative Medical Technology
Creative Medical Technology Holdings, Inc. (CMTH) is a clinical-stage biotechnology company focused on treating sexual dysfunction and infertility using stem cell treatments. Since 2011 Creative Medical Technology Holdings, Inc. (CMTH) and our affiliate company Creative Medical Health, Inc. have focused on regenerative medical solutions for both male and female virility and fertility. Through our own research and collaborations with leading academic institutions, CMT has developed proprietary protocols, built an extensive intellectual property portfolio, developed complete treatment offerings for erectile dysfunction and male infertility and are breaking new ground for new treatments in female sexual dysfunction and fertility. Our team consists of leading international researchers in regenerative medicine. Our “science-first” approach to treatments ensures that all of our treatments are proven to be both safe and effective.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Timothy Warbington
CFO: Donald Dickerson
CSO: Annette Marleau
58 articles about Creative Medical Technology
-
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
3/6/2024
Creative Medical Technology Holdings, Inc. is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration for CELZ-101, ImmCelzTM.
-
Creative Medical Technology Holdings Provides Corporate Update
6/12/2023
Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, provided an update on recent business activities.
-
Creative Medical Technology Announces $2 Million Share Repurchase Program
6/12/2023
Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, announced that its Board of Directors has approved a share repurchase program.
-
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
5/22/2023
Creative Medical Technology Holdings, Inc. announced significant advances in the ongoing development of its ImmCelz® platform, the Company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders.
-
Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes
3/23/2023
Creative Medical Technology Holdings, Inc. announced that it filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for the treatment of Brittle Type 1 Diabetes using its ImmCelz® platform.
-
Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes
11/3/2022
Creative Medical Technology Holdings, Inc. today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™.
-
Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line
10/20/2022
Creative Medical Technology Holdings, Inc. announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem.
-
Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform
6/15/2022
Creative Medical Technology Holdings, Inc., a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell pipeline for the Company's ImmCelz® platform.
-
Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product
4/20/2022
Creative Medical Technology Holdings, Inc. today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ImmCelz® product was produced in less than 72 hours, utilizing the Company's cell-free supercharging solution.
-
Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer
3/2/2022
Creative Medical Technology Holdings, Inc. announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022.
-
Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market
12/3/2021
Creative Medical Technology Holdings, Inc. announced the pricing of the underwritten public offering of 3,875,000 shares of common stock and accompanying warrants to purchase up to 3,875,000 shares of common stock at a combined public offering price of $4.13.
-
Creative Medical Technology Holdings Announces MyeloCelz™ The Company's Second Regenerative Immunotherapy Product
7/20/2021
Creative Medical Technology Holdings Inc. announced today the launching of its second Regenerative Immunology product, MyeloCelz™.
-
Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance
6/22/2021
Courtney Bartlett DNP, ACNP-BC, RNFA to Lead Clinical Translation of Company's Regenerative Immunotherapy Pipeline
-
Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference
6/17/2021
Creative Medical Technology Holdings, Inc., announced that the company will virtually present at the Investor Forum at the World Stem Cell Summit Thursday, June 17, 2021 at 12:00pm Eastern Standard Time and will consist of a 20-minute formal description of the Company followed by a 20-minute Q&A session moderated by a Noble Capital Markets equity research representative.
-
Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes
6/9/2021
Clinical Stage Regenerative Immunotherapy Company Optimizes Treatment for Diabetes as it Prepares for Additional Investigational New Drug Application.
-
Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease
5/24/2021
Clinical Stage Biotechnology Company Reports Patent Filing based on Preclinical Data using Regenerative Immunotherapy Approach
-
Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine
3/23/2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician™ focused on telehealth solutions for regenerative medicine this summer.
-
Creative Medical Technology Holdings, Inc. Announces FDA Acknowledgment of IND Application for ImmCelz® to Treat Stroke
3/16/2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that the FDA issued IND Number 27375 to the Company in connection with its Clinical Trial application
-
Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®
2/16/2021
Creative Medical Technology Holdings, Inc. announced filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of transplanted organs.
-
Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz® Regenerative Immunotherapy
12/31/2020
Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of heart attack.